Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.

@article{McMillan2011AntitumorEO,
  title={Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.},
  author={Sarah K McMillan and Pedro A Boria and George Edward Moore and William R. Widmer and Patty L. Bonney and Deborah W Knapp},
  journal={Journal of the American Veterinary Medical Association},
  year={2011},
  volume={239 8},
  pages={1084-9}
}
OBJECTIVE-To evaluate the antitumor activity and toxic effects of deracoxib, a selective cyclooxygenase-2 inhibitor, in dogs with transitional cell carcinoma (TCC) of the urinary bladder. DESIGN-Clinical trial. Animals-26 client-owned dogs with naturally occurring, histologically confirmed, measurableTCC of the urinary bladder. PROCEDURES-Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Intensity-modulated and image-guided radiation therapy for treatment of genitourinary carcinomas in dogs.

Journal of veterinary internal medicine • 2012
View 10 Excerpts
Highly Influenced

2016 AAHA Oncology Guidelines for Dogs and Cats.

Journal of the American Animal Hospital Association • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…